Anne E. Calvaresi, DNP, CRNP, RNFA, also discusses best practices that urologists and APPs can follow to ensure they work together well as a team and offers her opinion on the controversy surrounding the use of APPs for performing certain urologic procedures.
The aging urologist population has heightened the importance of advanced-practice providers (APPs) in urology practices, says Anne E. Calvaresi, DNP, CRNP, RNFA, a nurse practitioner at Thomas Jefferson University Hospital in Philadelphia.
Dr. Calvaresi, in this Urology Times video, offers some practical tips for integrating nurse practitioners and physician assistants into your urology practice. She also discusses best practices that urologists and APPs can follow to ensure they work together well as a team and offers her opinion on the controversy surrounding the use of APPs for performing certain urologic procedures.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.